Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Non-Current Debt: 2024-2025

Historic Non-Current Debt for Apellis Pharmaceuticals (APLS) over the last 2 years, with Sep 2025 value amounting to $361.1 million.

  • Apellis Pharmaceuticals' Non-Current Debt rose 0.59% to $361.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $361.1 million, marking a year-over-year increase of 0.59%. This contributed to the annual value of $359.5 million for FY2024, which is N/A change from last year.
  • Per Apellis Pharmaceuticals' latest filing, its Non-Current Debt stood at $361.1 million for Q3 2025, which was up 0.15% from $360.5 million recorded in Q2 2025.
  • Over the past 5 years, Apellis Pharmaceuticals' Non-Current Debt peaked at $364.0 million during Q2 2024, and registered a low of $359.0 million during Q3 2024.
  • Over the past 2 years, Apellis Pharmaceuticals' median Non-Current Debt value was $360.3 million (recorded in 2025), while the average stood at $360.7 million.
  • Examining YoY changes over the last 5 years, Apellis Pharmaceuticals' Non-Current Debt showed a top increase of 0.59% in 2025 and a maximum decrease of 0.96% in 2025.
  • Quarterly analysis of 2 years shows Apellis Pharmaceuticals' Non-Current Debt stood at $359.5 million in 2024, then grew by 0.59% to $361.1 million in 2025.
  • Its last three reported values are $361.1 million in Q3 2025, $360.5 million for Q2 2025, and $360.0 million during Q1 2025.